Insight

Frank A. Giordano: CXCL12 and VEGF Inhibition Glioblastoma

Photo of Frank A. Giordano taken from nachrichten.idw-online.de

Sep 18, 2024, 13:04

Frank A. Giordano: CXCL12 and VEGF Inhibition Glioblastoma

Frank A. Giordano, Chair Deptartement of Radiation Oncology at University Medical Center Mannheim, shared on LinkedIn:

“Glioblastoma remains one of the most challenging cancers to treat. Our latest research focuses on blocking CXCL12 and VEGF. By inhibiting both, we’re seeing promising advancements in improving patient outcomes and offering new hope in a space where effective treatments are critically needed.

It’s incredible to be part of a fantastic team pushing the boundaries in brain cancer care: Thank you Julian Layer, Michael Hölzel, Nils Nicolay, Clemens Seidel, Ghazaleh Tabatabai, Sonia Leonardelli, Elena Sperk, Michael Platten, Sotirios Bisdas, Sied Kebir and TME Pharma for all your support and your continuous trust in us.”

Frank A. Giordano

Source: Frank A. Giordano/LinkedIn

cancer Clemens Seidel Elena Sperk Frank A. Giordano Ghazaleh Tabatabai glioblastoma Julian Layer Michael Hölzel Michael Platten Nils Nicolay OncoDaily Oncology Sied Kebir Sonia Leonardelli Sotirios Bisdas TME Pharma

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage